Table III.
Demographic and disease characteristics of patients with mild SARS-CoV-2 infection (study 1.2).
| Characteristic | CT-P59 20 mg/kg (n = 5) |
CT-P59 40 mg/kg (n = 5) |
CT-P59 80 mg/kg (n = 5) |
Placebo (n = 3) |
Total (N = 18) |
|---|---|---|---|---|---|
| Age, median (IQR), y | 59.0 (56–59) |
51.0 (48–52) |
52.0 (43–57) |
50.0 (49–57) |
52.0 (49–57) |
| Male sex, No. (%) | 2 (40) | 2 (40) | 5 (100) | 2 (66.7) | 11 (61.1) |
| Race, No. (%) | |||||
| White | 0 | 5 (100) | 5 (100) | 2 (66.7) | 12 (66.7) |
| Asian | 5 (100%) | 0 | 0 | 1 (33.3) | 6 (33.3) |
| BMI, median (IQR), kg/m2, | 24.610 (24.34–25.96) | 26.890 (23.01–30.86) | 28.630 (27.46–29.40) |
27.770 (24.45–27.80) | 27.175 (24.45–28.63) |
| Time since symptom onset, median (IQR), d* | 4.0 (3–5) |
6.0 (5–6) |
4.0 (4–4) |
4.0 (4–6) |
4.0 (4–5) |
| Quantitative RT-PCR Ct value, mean (SD) | 24.406 (5.0934) | 28.176 (6.6642) | 24.651 (5.5092) | 24.827 (7.7960) | 25.516 (6.2297) |
BMI = body mass index; Ct = cycle threshold; IQR = interquartile range; RT-PCR = reverse transcription–polymerase chain reaction.
⁎
Number of days is calculated as [date of study drug administration − first start date of SARS-CoV-2 infection-associated symptoms + 1].